文献速递泌尿男性生殖肿瘤

铽-161[161Tb]Tb-PSMA-I&T双β-Auger放射配体治疗转移性去势抵抗性前列腺癌患者的首次人体研究结果(VIOLET):一项单中心、单臂、1/2期研究

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
PubMed 文献 · Lancet Oncol · 2025-07-03

VIOLET研究在30例转移性去势抵抗性前列腺癌患者中评估[161Tb]Tb-PSMA-I&T的安全性,采用3+3剂量递增设计,三个预设放射性活度为4.4 GBq、5.5 GBq和7.4 GBq,每6周静脉给药,最多6个周期。未观察到剂量限制性毒性,最大给药剂量和推荐的2期剂量为7.4 GBq,3级治疗相关不良事件仅疼痛和淋巴细胞减少各1例(3%),无4级不良事件或治疗相关死亡。作者认为[161Tb]Tb-PSMA-I&T在7.4 GBq最大给药剂量下安全,需在更大规模随机临床试验中进一步研究。

要点

  • 30例mCRPC患者中未观察到剂量限制性毒性,最大给药剂量和推荐2期剂量为7.4 GBq。
  • 3级治疗相关不良事件仅疼痛(1例[3%],唯一严重不良事件)和淋巴细胞减少(1例[3%])。
  • 无4级治疗相关不良事件或治疗相关死亡,无因毒性减量或停药。

核心结论

  • [161Tb]Tb-PSMA-I&T在最大给药剂量7.4 GBq下安全。
  • 作者认为需在更大规模随机临床试验中进一步研究这一有前景的放射性核素。

研究设计与样本

  • VIOLET为研究者发起的单中心1/2期试验,在澳大利亚墨尔本Peter MacCallum癌症中心开展。
  • 纳入30例年龄≥18岁、既往接受雄激素受体通路抑制剂和紫杉烷化疗(除非医学上不适合)的进展性mCRPC男性患者,ECOG体能状态0-2,PSMA PET-CT最大标准化摄取值≥20且FDG PET-CT无不一致。
  • 剂量递增采用3+3设计,三个预设放射性活度为4.4 GBq、5.5 GBq和7.4 GBq。
  • 最多6个周期[161Tb]Tb-PSMA-I&T每6周静脉给药,每周期减少0.4 GBq。
  • 1期主要终点为剂量限制性毒性、最大耐受剂量和推荐2期剂量,2期主要目的为按CTCAE v5.0评估不良事件。

主要发现

  • 2022年10月14日至2024年2月15日共入组30例符合条件患者,中位年龄69.0岁(IQR 66.0-74.8),筛查PSA 26.9 ng/mL(10.1-70.0),PSMA平均标准化摄取值8.2(7.4-10.8),20例(67%)既往接受过多西他赛。
  • 未观察到剂量限制性毒性,最大给药剂量和推荐2期剂量为7.4 GBq。
  • 3级治疗相关不良事件仅疼痛(1例[3%],唯一严重治疗相关不良事件)和淋巴细胞减少(1例[3%])。
  • 无4级治疗相关不良事件或治疗相关死亡,无因毒性减量或停药。

关键数值与推荐

  • 剂量递增三个预设放射性活度:4.4 GBq、5.5 GBq、7.4 GBq。
  • 最大给药剂量和推荐2期剂量为7.4 GBq。
  • 每6周静脉给药,最多6个周期,每周期减少0.4 GBq。
  • 3级治疗相关不良事件:疼痛1例(3%),淋巴细胞减少1例(3%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 本文为中期分析,随访仍在进行中,并重新开放招募额外剂量水平(9.5 GBq)。
  • 作者认为需在更大规模随机临床试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Terbium-161 (161Tb) emits beta-radiation similar to lutetium-177 (177Lu), with additional radiation over ultra-short path lengths from Auger electrons. 161Tb has shown superior in-vitro and in-vivo efficacy compared with 177Lu. We aimed to evaluate the safety of [161Tb]Tb-PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: VIOLET was an investigator-initiated, single-centre, phase 1/2 trial, conducted at the Peter MacCallum Cancer Centre (Melbourne, VIC, Australia). Eligible patients were men aged 18 years or older with progressive mCRPC (histologically or cytologically confirmed adenocarcinoma of the prostate or unequivocal diagnosis of metastatic prostate cancer with an elevated serum prostate specific antigen) previously treated with an androgen receptor pathway inhibitor and taxane chemotherapy (unless medically unsuitable), Eastern Cooperative Oncology Group performance status of 0-2, and prostate-specific membrane antigen (PSMA) positivity (maximum standardised uptake value ≥20 on PSMA PET-CT) without discordance on 2-[18F]fluoro-2-deoxy-D-glucose (FDG) PET-CT. Dose escalation (3 + 3 design) had three prespecified radioactivities (4·4 GBq, 5·5 GBq, and 7·4 GBq). Up to six cycles of [161Tb]Tb-PSMA-I&T were administered intravenously every 6 weeks, reduced by 0·4 GBq for each cycle. Primary endpoints of phase 1 were dose-limiting toxicities, the maximum tolerated dose, and the recommended phase 2 dose, and the primary objective of phase 2 was evaluation of adverse events as defined by Common Terminology Criteria for Adverse Events version 5.0. We present here an interim analysis, with follow-up ongoing and recruitment reopened for an additional dose level (9·5 GBq). The trial is registered at ClinicalTrials.gov (NCT05521412). FINDINGS: Between Oct 14, 2022 and Feb 15, 2024, 30 eligible patients were enrolled. Median age was 69·0 years (IQR 66·0-74·8), screening PSA 26·9 ng/mL (10·1-70·0), PSMA mean standardised uptake value 8·2 (7·4-10·8), and 20 (67%) of 30 patients had received previous docetaxel. There were no dose-limiting toxicities. The maximum administered dose and recommended phase 2 dose was 7·4 GBq. Grade 3 treatment-related adverse events (TRAEs) were limited to pain (one [3%] of 30; the only serious TRAE) and lymphopenia (one [3%] of 30). No grade 4 TRAEs or treatment-related deaths occurred. No dose reductions or treatment discontinuation occurred for toxicity. INTERPRETATION: [161Tb]Tb-PSMA-I&T is safe at the maximum administered dose of 7·4 GBq. Further investigation of this promising radionuclide is warranted in larger, randomised clinical trials. FUNDING: Prostate Cancer Foundation, Peter MacCallum Cancer Foundation, National Health and Medical Research Council Investigator Grant, Isotopia Molecular Imaging.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Buteau JP, Kostos L, Jackson PA, et al. First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study. Lancet Oncol. 2025. PMID: 40617237. doi:10.1016/S1470-2045(25)00332-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。